A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
NA
This multicenter, open-label, prospective cohort clinical study enrolled 70...
Status
Terminated
Location
Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
PHASE2
This trial studies the effects on quality of life and on time to second pro...